アステラス製薬は、TME iLab テクノロジーイノベーションセンターの設立を発表しました。

Astellas Pharma has announced that they will establish an open innovation center for “TME Imaging and Interactive Research (TME iLab) in October 2023 in Kashiwa City. Operated by Mitsui Fudosan, the two companies will collaborate with the aim of maximizing profits, and are perfectly located near the National Cancer Center in Japan.

The TME iLab aims to generate innovation through discussion between internal and external researchers, including Dr. Akihiro Ohasi, division head of Collaborative Research and Development at the Clinical Trials Center, who is himself a principal investigator on the project.

Specifically, they will analyze spatial information and state-of-the-art machine learning technologies, such as the special molecular imager “COsMx SMI”, the spatial omics analysis system “Xenium” and the multifluorescent tissue profiler “Orion”, from NanoString, 10x Genomics and RareCyte respectively.

In addition, Mitsui Fudosan will provide the “Mitsui Link Lab Open Innovation Support Program” to create a mechanism to attract many researchers to TME iLab and provide business and research support.

Its chief scientific officer, Yoshitsugu Shitaka, says they are pleased to enter into an agreement with Mitsui Fudosan to develop “a new open innovation center,” as they are looking for a wide range of partners with expertise and innovative technologies in tumor microenvironment research.

On behalf of Kazunori Yamashita, CEO of Mitsui Fudosan, he welcomed Astellas for establishing a center in Kashiwa-no-ha, an area that is building a smart city through public-private collaboration.

You can read the complete news in the following link.